TFS
TARS icon

Thoroughbred Financial Services’s Tarsus Pharmaceuticals TARS Stock Holding History

Thoroughbred Financial Services’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,725
Closed -$223K – 603
2025
Q4 		$223K Buy
+2,725
New +$203K 0.01% 534
2025
Q2 		– Sell
-5,510
Closed -$283K – 695
2025
Q1 		$283K Buy
5,510
+765
+16% +$37.8K 0.02% 560
2024
Q4 		$262K Buy
+4,745
New +$216K 0.02% 579
2024
Q2 		– Sell
-20,964
Closed -$762K – 648
2024
Q1 		$762K Buy
+20,964
New +$616K 0.07% 238

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Thoroughbred Financial Services's TARS Position: Q1 2026 in Review

Thoroughbred Financial Services sold out of Tarsus Pharmaceuticals (TARS) in Q1 2026, closing a stake of 2,725 shares — an estimated $223K sold.

Thoroughbred Financial Services first reported a position in TARS in Q1 2024 and held it in 4 quarters. The position peaked at $762K in Q1 2024. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Thoroughbred Financial Services reported no remaining Tarsus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Thoroughbred Financial Services sold 2,725 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $223K.
  • Thoroughbred Financial Services first reported a position in Tarsus Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Thoroughbred Financial Services's Tarsus Pharmaceuticals position peaked at $762K in Q1 2024.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Thoroughbred Financial Services's 13F filing for Q1 2026, filed 12 May 2026.